Objectives: Pleural fluid metastasis occurs often secondary to a known primary tumor. We aim to identify the percentage of adenocarcinomas metastatic to pleural effusion in women and the frequency of another primary tumor being the origin of the effusion using morphology and immunostains. Study Design: One hundred and thirty-one cases from our archives were reviewed. Results: Ninety-four percent had a documented primary. The breast was the most common site (34%); less common were the lung and ovary, and 7.9% had two different primaries. Seven cases proved to be secondary to an adenocarcinoma other than the one on record. Lung tumors were the most common overlooked tumors (5/7 cases). Six percent remained of inconclusive origin due to an occult primary, absent cells on cell blocks, or discordance with radiology or cytology of a known primary. Morphology in association with a small panel of immunostains including thyroid transcription factor 1, estrogen receptor, mammaglobin, Wilms tumor antigen 1, CA125 and CDX2 proved helpful in identifying the primary origin in 94% of cases. Conclusion: After a morphological comparison with previously available material, and due to major implications in the therapeutic strategy, a small panel of immunostains is advised on available cell block material to verify the origin of the metastatic effusion.

Vargas FS, Teixeira LR: Pleural malignancies. Curr Opin Pulm Med 1996;2:335–340.
Dharan M: Unilateral pleural effusion as a presenting manifestation of plasma cell myeloma (multiple myeloma): a case report. Acta Cytol 2010;54:780–782.
Antic T, Staerkel G: Mediastinal epithelioid hemangioendothelioma metastatic to lymph nodes and pleural fluid: report of a case. Diagn Cytopathol 2010;38:113–116.
Inoue J, Gomibuchi H, Minoura S: A case of a primary ovarian leiomyosarcoma. J Obstet Gynaecol Res 2000;26:401–407.
Cibas ES, Ducatman BS: Cytology Diagnostic Principles and Clinical Correlates, ed 3. Philadelphia, Saunders, 2009, p 135.
Monte SA, Ehya H, Lang WR: Positive effusion cytology as the initial presentation of malignancy. Acta Cytol 1987;31:448–452.
Sears D, Hajdu SI: The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions. Acta Cytol 1987;31:85–97.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer Staging Manual, ed 7. New York, Springer, 2010.
Fang F, Yang L, Su XL, He Q, Liu DG, Lin FR, et al: Determining the primary site of metastatic adenocarcinoma in serous fluid: a cytological study. Zhonghua Bing Li Xue Za Zhi 2005;34:641–645.
Jang KY, Kang MJ, Lee DG, Chung MJ: Utility of thyroid transcription factor-1 and cytokeratin 7 and 20 immunostaining in the identification of origin in malignant effusions. Anal Quant Cytol Histol 2001;23:400–404.
Longatto FA, Alves VA, Kanamura CT, Nonogaki S, Bortolan J, Lombardo V, et al: Identification of the primary site of metastatic adenocarcinoma in serous effusions. Value of an immunocytochemical panel added to the clinical arsenal. Acta Cytol 2002;46:651–658.
Fiel MI, Cernaianu G, Burstein DE, Batheja N: Value of GCDFP-15 (BRST-2) as a specific immunocytochemical marker for breast carcinoma in cytologic specimens. Acta Cytol 1996;40:637–641.
Rehman F, Nagi AH, Hussain M: Immunohistochemical expression and correlation of mammaglobin with the grading system of breast carcinoma. Indian J Pathol Microbiol 2010;53:619–623.
Yang M, Nonaka D: A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol 2010;23:654–661.
Vollmer RT: Primary lung cancer vs metastatic breast cancer: a probabilistic approach. Am J Clin Pathol 2009;132:391–395.
Yan Z, Gidley J, Horton D, Roberson J, Eltoum IE, Chhieng DC: Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens. Diagn Cytopathol 2009;37:475–478.
Ashton PR, Hollingsworth AS Jr, Johnston WW: The cytopathology of metastatic breast cancer. Acta Cytol 1975;19:1–6.
Wiley EL, Von Roenn J: Metastatic breast carcinoma in pleural fluid. Correlation of morphology with estrogen receptor activity and morphology of the primary carcinoma. Acta Cytol 1990;34:169–174.
Danner DE, Gmelich JT: A comparative study of tumor cells from metastatic carcinoma of the breast in effusions. Acta Cytol 1975;19:509–518.
Zhu W, Michael CW: WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol 2007;35:370–375.
Loy TS, Quesenberry JT, Sharp SC: Distribution of CA 125 in adenocarcinomas. An immunohistochemical study of 481 cases. Am J Clin Pathol 1992;98:175–179.
Kim JH, Kim YS, Choi YD, Lee JS, Park CS: Utility of napsin A and thyroid transcription factor 1 in differentiating metastatic pulmonary from non-pulmonary adenocarcinoma in pleural effusion. Acta Cytol 2011;55:266–270.
Dorval M, Noguès C, Berthet P, Chiquette J, Gauthier-Villars M, Lasset C, et al: Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec. Eur J Hum Genet 2011;19:494–499.
Metcalfe K, Lubinski J, Lynch HT, Ghadirian P, Foulkes WD, Kim-Sing C, et al: Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst 2010;102:1874–1878.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.